Neuroblastoma

This study tests a drug called apatinib combined with two chemotherapy drugs (irinotecan and temozolomide) in children aged 5 to 18 with neuroblastoma that has returned or not improved after standard treatment. The goal is to see if the combination can shrink tumors and help chil…

This early-phase trial tested whether giving activated natural killer (NK) cells, with or without a protein called rhIL15, is safe and feasible for children and young adults with solid tumors that didn't respond to other treatments. Sixteen participants received chemotherapy to l…

This phase 2 trial is testing whether combining two chemotherapy drugs—temozolomide and topotecan—can help children with neuroblastoma, brain tumors, or other solid tumors that have come back or not responded to standard treatment. Participants receive temozolomide by mouth and t…

This phase 2 trial is testing whether combining two chemotherapy drugs, gemcitabine and oxaliplatin, can shrink tumors in children and adolescents with certain solid cancers that have come back or not responded to standard treatment. The study includes patients with medulloblasto…

This trial tests a vaccine designed to help the immune system recognize and attack neuroblastoma, a type of childhood cancer. The vaccine contains two antigens found on neuroblastoma cells, plus an adjuvant to boost the immune response. Participants also take an oral supplement c…

People with inflammatory bowel disease (IBD) have a higher risk of colorectal cancer and need regular colonoscopies to catch early warning signs. This study compares two techniques—narrow-band imaging (a special light) and an artificial intelligence (AI) system—to see which finds…

This phase 3 trial tested the safety of giving a monoclonal antibody (dinutuximab) along with immune-boosting drugs and a vitamin-like drug to children with high-risk neuroblastoma after a stem cell transplant. The goal was to see if this combination could be given safely and hel…

This study tested whether adding two immunotherapy drugs (dinutuximab and GM-CSF) to standard chemotherapy is safe and doable for children newly diagnosed with high-risk neuroblastoma. Forty-two children took part. The goal was to see if the extra drugs cause too many side effect…

This study tested whether adding the drug bevacizumab (Avastin) to standard chemotherapy helps children with neuroblastoma that has returned or not responded to treatment. The trial enrolled 225 children aged 1 to 21. Researchers looked at tumor shrinkage and how long the disease…

This phase 2 trial tested a combination of a radioactive drug (MIBG), intensive chemotherapy, and a stem cell transplant in 50 children with relapsed or hard-to-treat neuroblastoma. The goal was to see if this approach could shrink tumors and improve survival. The treatment aims …

This early-stage trial tested a radioactive drug called 177Lu-DOTATATE in one child with neuroblastoma that had come back or not responded to standard treatments. The drug targets tumor cells that have a specific marker (somatostatin receptors). The goal was to find a safe dose. …

This phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…

This early-phase study tested a combination of three oral drugs (irinotecan, temozolomide, and cefixime) in 30 children whose high-risk neuroblastoma had come back or not responded to standard treatment. The goal was to find the safest dose of irinotecan when given with the other…

This early-phase study tested an intravenous form of the drug fenretinide in 17 children whose neuroblastoma had come back or didn't respond to standard treatments. The main goals were to find the safest dose and understand side effects. Researchers also looked at how the drug mo…

This early-phase study tested a new approach for children with neuroblastoma that did not respond to standard treatments. It used two rapid infusions of a radioactive drug (I-MIBG) to target cancer cells, followed by a stem cell transplant to restore healthy blood cells. The goal…

This study tested a new antibody (hu14.18K322A) added to standard chemotherapy for 153 children with high-risk neuroblastoma, a serious nerve tissue cancer. The goal was to see if the combination improves tumor shrinkage and delays the cancer from coming back. While the treatment…

This early-phase study tested a combination of two chemotherapy drugs (irinotecan and vincristine) plus a radioactive drug (131I-MIBG) in 26 children with high-risk neuroblastoma that had come back or not responded to standard treatment. The goal was to find the safest dose of th…

This early-stage trial tested a new oral form of the chemotherapy drug fenretinide in 80 children whose neuroblastoma had come back or resisted standard treatment. The goal was to find the safest dose and understand side effects. Researchers also looked at how the body processes …

This study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…

This study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…

This study tested whether adding an immunotherapy drug (dinutuximab) and immune-boosting medicines to standard treatment helps children with high-risk neuroblastoma stay cancer-free longer. About 1,400 children who had already received intensive chemotherapy and a stem cell trans…

This study tested an experimental drug called ENV-101 (taladegib) in 20 adults with advanced solid tumors that have a specific genetic mutation (PTCH1 loss-of-function). The drug works by blocking a growth pathway in cancer cells. Researchers measured how many patients' tumors sh…

This study tested the safety and effectiveness of the drug abemaciclib combined with other cancer medicines in 47 children and young adults whose solid tumors (including neuroblastoma) had stopped responding to standard treatments. The goal was to find the best dose and see if th…

This early-phase study tested a new drug called CUDC-907 in 26 children and young adults (ages 1-21) with cancers that had come back or stopped responding to treatment, including solid tumors, brain tumors, and lymphoma. The main goal was to find a safe dose and check for side ef…

This study tested a new way to do stem cell transplants in 23 children with cancers that came back or didn't respond to treatment. The method removes certain immune cells from the donor's stem cells to help the child's body recover faster and fight infections better. The goal was…

This study tested a very strong treatment plan for children newly diagnosed with high-risk neuroblastoma, a serious nerve cell cancer. The approach combined intensive chemotherapy, a radioactive drug called 131I-MIBG, and a stem cell transplant to try to kill more cancer cells. T…

This study tested a new treatment for children with high-risk neuroblastoma, a type of cancer. Researchers took the patients' own immune cells (T cells) and modified them to recognize and attack the cancer. Some of these cells were also trained to fight a common virus (EBV) to he…

This study tested whether adding an immunotherapy drug (Hu3F8) plus GM-CSF to standard treatment could help children with high-risk neuroblastoma stay in remission longer. Fifty-nine children who had already achieved remission after initial therapy received the combination along …

This early-phase trial tested a reduced dose of radiation in 78 children with high-risk neuroblastoma. The goal was to see if a lower dose could still control the tumor while causing fewer long-term side effects. Researchers monitored local control rates and side effects over tim…

This early-stage trial tested a drug called lorlatinib in 65 children and young adults with a type of nerve cancer (neuroblastoma) that had come back or not responded to treatment. The drug targets a specific genetic change (ALK) found in their tumors. The study looked at safety,…

This Phase 3 trial tests a radioactive imaging agent called 18F-mFBG to see if it can accurately detect neuroblastoma, a type of childhood cancer. The study involves 43 participants who either have or are suspected of having neuroblastoma. Researchers will compare the new PET sca…

This trial is testing whether an artificial intelligence (AI) model can accurately diagnose and grade several types of solid tumors that affect children, including neuroblastoma, medulloblastoma, Wilms tumor, hepatoblastoma, and rhabdomyosarcoma. The AI is trained on thousands of…

This study gave a radioactive drug called 131I-MIBG to 15 people with advanced nerve tumors (neuroblastoma or pheochromocytoma) that had stopped responding to standard treatments. The goal was to see if it could ease symptoms and shrink tumors, while tracking side effects. Partic…

This study is testing whether a green dye called ICG can help surgeons see tumors more clearly during surgery in children and teens with solid tumors. The dye is injected before surgery and makes tumor tissue glow under a special camera. The goal is to see if this technique helps…

This study collects and analyzes tumor tissue from up to 10,000 children newly diagnosed with neuroblastoma or related tumors. Researchers look for biomarkers—like DNA changes and gene activity—that may help predict how the disease will behave. The goal is to better understand th…

This study looked at 119 children who had platinum-based chemotherapy for certain cancers. Researchers wanted to find out if certain genes make some kids more likely to develop hearing loss from the treatment. By analyzing DNA from saliva samples, they hope to identify high-risk …

This study tested whether analyzing the DNA and RNA of a child's tumor could help doctors choose personalized treatments. It included 186 children with relapsed or hard-to-treat cancers like neuroblastoma and brain tumors. The goal was to see if this approach was feasible and saf…